Email updates

Keep up to date with the latest news and content from BMC Infectious Diseases and BioMed Central.

Open Access Highly Accessed Research article

Therapy of intracellular Staphylococcus aureus by tigecyclin

Carolin A Kreis1*, Michael J Raschke1, Steffen B Roßlenbroich1, Nancy Tholema-Hans1, Bettina Löffler2 and Thomas Fuchs1

Author Affiliations

1 Department of Trauma, Hand and Reconstructive Surgery, University Hospital of Muenster, Waldeyerstr. 1, 48149, Muenster, Germany

2 Institute of Medical Microbiology, University Hospital of Muenster, Domagkstr. 10, 48149, Muenster, Germany

For all author emails, please log on.

BMC Infectious Diseases 2013, 13:267  doi:10.1186/1471-2334-13-267

Published: 5 June 2013

Abstract

Background

In the fields of traumatology and orthopaedics staphylococci are the most frequently isolated pathogens. Staphylococcus aureus and Staphylococcus epidermidis are known to be the major causative agents of osteomyelitis. The increasing number of multiresistant Staphylococcus aureus and resistant coagulase-negative staphylococci as a trigger of complicated osteomyelitis and implant-associated infections is a major problem. Antibiotic therapy fails in 20% of cases. Therefore the development of novel antibiotics becomes necessary.

Methods

This study analyses tigecyclin, the first antibiotic of the glycylines, as a potential therapy for osteomyelitis caused by multiresistant Staphylococcus aureus. Therefore its intracellular activity and the potential use in polymethylmetacrylate-bone cement are examined. The intracellular activity of tigecyclin is determined by a human osteoblast infection model. The investigation of the biomechanical characteristics is conducted concerning the ISO 5833-guidelines.

Results

Tigecyclin shows in vitro an intracellular activity that ranges between the antimicrobial activity of gentamicin and rifampicin. A significant negative effect on the biomechanical characteristics with an impaired stability is detected after adding tigecyclin to polymethylmetacrylate-bone cement with a percentage of 1.225% per weight.

Conclusions

This study shows that tigecyclin might be a potent alternative for the systemic therapy of osteomyelitis and implant-associated infections whereas the local application has to be reconsidered individually.

Keywords:
Osteomyelitis; Implant associated infection; Staphylococcus aureus; Tigecyclin; Biomechanical stability